Vitamin D3 + K2: What the Research Shows — A Pharmacist's Evidence Review

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Clinical Question

Vitamin D3 is one of the most commonly recommended supplements in modern medicine. Deficiency is widespread in northern latitudes and among populations with limited sun exposure, and a substantial body of research links low vitamin D status to bone, immune, and cardiovascular health outcomes. A more recent question has emerged: does co-supplementation with Vitamin K2 meaningfully improve outcomes compared to D3 alone?

This article reviews what each nutrient does, what the human clinical evidence supports, and where the evidence is still developing — so you can make an informed decision with your pharmacist or physician.

Vitamin D3: What It Does and What the Evidence Shows

Vitamin D3 (cholecalciferol) is synthesized in the skin on UVB exposure and converted in the liver and kidneys to its active hormonal form, calcitriol. Vitamin D receptors are present on most cell types, giving it broad biological relevance.

Well-established functions:

• Calcium absorption: D3 substantially increases intestinal calcium absorption; deficiency impairs calcium uptake regardless of dietary intake.
• Bone mineralization: Vitamin D is essential for normal bone mineralization. Correcting deficiency is clinically important for prevention of osteomalacia and for bone health in older adults. However, vitamin D supplementation alone has not consistently reduced fractures in generally healthy, vitamin-D-replete adults; benefit appears to depend on baseline deficiency status, calcium status, population, and dosing regimen (see evidence section below).
• Immune modulation: Vitamin D receptors are present on immune cells and have a role in innate and adaptive immune responses.

Evidence still developing:

• Associations between low vitamin D and cardiovascular disease, cancer, and mood disorders are well-documented epidemiologically, but large RCTs — including the VITAL trial (PMID: 30415629) — have produced mixed results on whether supplementation reduces these outcomes in populations that are not frankly deficient. Correcting documented deficiency remains clinically important; routine high-dose supplementation in vitamin-D-replete individuals is less clearly supported.

Who Is at Increased Risk for Vitamin D Deficiency?

• People with limited sun exposure or who live in northern latitudes (above 37°N — which includes San Jose, CA)
• Individuals with darker skin pigmentation
• Adults over 65 (skin synthesis efficiency declines with age)
• Individuals with obesity (vitamin D is sequestered in fat tissue)
• Patients with malabsorption conditions (Crohn’s, celiac, post-bariatric surgery)
• Patients on medications that affect vitamin D metabolism (corticosteroids, anticonvulsants)
• Exclusively breastfed infants

A blood test measuring 25(OH)D levels is the standard way to assess status. Most clinical guidelines consider levels below 20 ng/mL deficient. Routine supplementation at 1,000–2,000 IU/day is considered low-risk for most healthy adults.

Vitamin K2: What It Does and What the Evidence Shows

Vitamin K2 (menaquinone) is distinct from Vitamin K1 (phylloquinone), which is primarily involved in coagulation. K2’s main biological role is activating two carboxylation-dependent proteins:

• Osteocalcin: A protein involved in bone matrix formation. K2 is required to carboxylate (activate) osteocalcin, which supports calcium incorporation into bone.
• Matrix Gla Protein (MGP): A protein that inhibits arterial calcification. K2 activates MGP; uncarboxylated MGP has been associated with increased arterial stiffness and calcification in observational research.

D3 increases intestinal calcium absorption, while vitamin K supports carboxylation of osteocalcin and matrix Gla protein. This provides a biological rationale for combined supplementation, but clinical evidence has not established that K2 universally prevents D3-associated soft-tissue calcium deposition.

MK-4 vs. MK-7: Which Form of K2?

• MK-7 (long-chain menaquinone): Derived from natto or fermentation. A human pharmacokinetic study (PMID: 23140417) found that MK-7 reached peak serum concentrations at approximately 6 hours after dosing and remained detectable for up to 48 hours with repeated dosing, whereas nutritional-dose MK-4 was not detectably increased in serum. MK-7 has substantially longer circulating persistence than MK-4, supporting once-daily supplementation. MenaQ7® (NattoPharma) is the most clinically studied MK-7 form. Generally preferred for supplementation.
• MK-4 (short-chain menaquinone): Shorter circulating half-life requires multiple daily doses. Used in older Japanese clinical trials at pharmacological doses (45 mg/day) for osteoporosis treatment — well above typical supplement doses.

Featured Product: Wiley’s Finest® Omega-3 with K2 & D3

Wiley’s Finest® Omega-3 with K2 & D3 (60 Softgels)

One softgel: 500 mg EPA+DHA (375 mg EPA + 125 mg DHA) from Wild Alaska Pollock • 80 mcg MenaQ7® K2 (MK-7) • 2,000 IU Vitamin D3. MSC-certified. Non-GMO.

Pharmacist’s Note: As a PharmD, I discuss this combination product with patients looking to address multiple nutrient gaps in a single daily dose. The use of MenaQ7® — the most clinically studied K2 form — is a meaningful quality distinction. Patients on warfarin should consult their pharmacist before starting any K2-containing supplement.

What Does the Human Clinical Evidence Show?

Vitamin D — Bone and Fractures

• META-ANALYSIS Bischoff-Ferrari HA et al., JAMA 2004 (PMID: 15113819): Meta-analysis of RCTs; D3 supplementation reduced fall risk by 22% in older adults.
• HUMAN RCT VITAL Fracture Analysis (PMID: 35939577) — 25,871 participants, D3 2,000 IU/day: Vitamin D3 did not significantly reduce total fractures, nonvertebral fractures, or hip fractures in generally healthy adults not selected for deficiency or osteoporosis.
• META-ANALYSIS 2024 PMID: 38997531 — 7 RCTs, 71,899 healthy older adults: No significant reduction in total fractures from vitamin D supplementation alone.

Grade: Vitamin D is essential for bone mineralization and correction of deficiency is clinically important. Vitamin D supplementation alone has NOT consistently reduced fractures in generally healthy, vitamin-D-replete adults. Benefit may depend on baseline deficiency, calcium status, population, and dosing.

Vitamin D — Respiratory Infections — MIXED / NOT CLEARLY ESTABLISHED

• META-ANALYSIS 2017 Martineau AR et al., BMJ 2017 (PMID: 28202713) — 25 RCTs, 11,321 participants: Reported a modest protective effect against acute respiratory infections overall; protective effect described as strongest in individuals with severe baseline deficiency (25(OH)D <25 nmol/L).
• META-ANALYSIS 2025 PMID: 39993397 — Updated 2025 meta-analysis, 40 studies, 61,589 participants (including 6 newer RCTs): Vitamin D did not significantly reduce overall acute respiratory infection risk (OR 0.94; 95% CI 0.88–1.00; P=0.057). Prespecified subgroup analyses did not find significant effect modification by baseline vitamin D status, age, dosing frequency, or dose size.

Grade: MIXED / NOT CLEARLY ESTABLISHED. The 2017 meta-analysis reported a modest benefit; the larger 2025 updated meta-analysis did not find a statistically significant overall effect. The earlier finding of stronger benefit in severely deficient individuals was not confirmed in the updated prespecified subgroup analysis.

Vitamin D — Cancer and Cardiovascular Outcomes — NOT ESTABLISHED (primary prevention)

• LARGE RCT (VITAL) Manson JE et al., NEJM 2019 (PMID: 30415629) — 25,871 participants, D3 2,000 IU/day: Did not significantly reduce primary cardiovascular or cancer endpoints in a generally vitamin-D-replete population. Secondary analyses suggested reduced cancer mortality with longer follow-up.

Grade: NOT ESTABLISHED for primary prevention of cardiovascular events or cancer in vitamin-D-replete adults.

MK-7 — Postmenopausal Bone Health — MODERATE / SUPPORTIVE

• HUMAN RCT Knapen MH et al., 2013 (PMID: 23525894) — 244 healthy postmenopausal women, MenaQ7® 180 mcg/day, 3 years: Significantly improved vitamin K status; attenuated age-related decline in BMD at lumbar spine and femoral neck; favorable effect on calculated bone-strength indices.
• HUMAN RCT PMID: 27625301 — 148 postmenopausal women with osteopenia, MK-7 375 mcg/day + calcium + vitamin D, 12 months: Substantially reduced undercarboxylated osteocalcin; preserved selected tibial trabecular microarchitecture vs. placebo. Note: adjunctive K2 effect in this population, not standalone D3+K2 superiority.
• HUMAN RCT PMID: 32060566 — 311 adults age 50–75, K2 50 or 90 mcg/day ± calcium + D3, 1 year: In postmenopausal women, femoral-neck bone loss was significantly lower in 90-mcg K2 groups vs. placebo. Effect was not demonstrated in men. Supports K2 relevance particularly in postmenopausal women.

K2 — Postmenopausal BMD Meta-Analyses — MODERATE / SUPPORTIVE

• META-ANALYSIS PMID: 36033779 — Meta-analysis, 16 RCTs, 6,425 participants: Significant improvement in lumbar-spine BMD with K2 and reductions in undercarboxylated osteocalcin. Six-RCT fracture analysis showed no significant fracture reduction overall (RR 0.96); benefit emerged in sensitivity analysis after excluding one heterogeneous study.

K2/postmenopausal BMD — MODERATE / SUPPORTIVE. K2/fracture prevention — MIXED / NOT FIRMLY ESTABLISHED.

D3 + K2 Combination — Bone and BMD — LIMITED-TO-MODERATE / SUPPORTIVE

• META-ANALYSIS PMID: 32219282 — 2020 meta-analysis, 8 RCTs, 971 participants, vitamin D + vitamin K: Significant improvement in total BMD; significant reduction in undercarboxylated osteocalcin; subgroup analysis suggested favorable effects when K2 was used.

Grade: LIMITED-TO-MODERATE / SUPPORTIVE. Studies vary substantially in population, formulation, and dosing. D3+K2 combination shows a stronger BMD signal than either alone in some analyses, but trial heterogeneity limits firm conclusions. The 80 mcg MK-7 + 2,000 IU D3 dose in Wiley’s has not been separately evaluated in these trials.

MK-7 — Arterial Stiffness and Vascular Calcification

• HUMAN RCT Knapen MH et al., 2015 (PMID: 25694037) — Healthy postmenopausal women, MK-7, long-term: Improved some measures of arterial stiffness, particularly among women with higher baseline stiffness.
• HUMAN RCT PMID: 31387121 — T2DM + established CVD, MK-7 360 mcg/day vs. placebo, 6 months: MK-7 significantly reduced inactive dp-ucMGP, demonstrating biological activity on the MGP pathway. However, it did not significantly reduce vascular calcification on conventional CT.
• HUMAN RCT 2026 Vossen et al., JAMA Cardiology 2026 (PMID: 42268593) — 180 patients with symptomatic CAD and baseline CAC 50–400 AU, MK-7 360 mcg/day vs. placebo, 2 years: Placebo group median CAC progressed from 145 to 214 AU; MK-7 group median CAC progressed from 135 to 184 AU. Between-group difference statistically significant (P=.02), with a similar finding for calcium mass. No significant adverse effects reported. The authors concluded that MK-7 may slow calcification in noncalcified plaques in patients with symptomatic CAD; however, the clinical significance for plaque stability and cardiovascular outcomes remains uncertain.
• PROSPECTIVE COHORT Rotterdam Study (PMID: 15514282) — Higher dietary K2 intake associated with reduced cardiovascular mortality: Prospective observational study based on dietary intake, not supplementation. Association, not causation.

MK-7 / arterial stiffness — LIMITED / SUPPORTIVE (one RCT, selected population). MGP carboxylation biomarkers — SUPPORTIVE HUMAN EVIDENCE. MK-7 / vascular calcification progression — LIMITED / EMERGING SUPPORTIVE EVIDENCE (2026 RCT showed statistically significant attenuation of CAC progression in symptomatic CAD patients; clinical significance for plaque stability and CV events remains uncertain). K2 cardiovascular-event prevention — NOT ESTABLISHED. Universal requirement for K2 whenever taking D3 — NOT ESTABLISHED.

Evidence Summary

Drug Interactions — Critical Information

• Warfarin (Vitamin K2): K2 can reduce warfarin’s anticoagulant effect. Patients on warfarin should not start K2 without physician supervision and INR monitoring. This applies to all vitamin K forms.
• Novel anticoagulants (apixaban, rivaroxaban): Less interaction than warfarin; pharmacist review is still recommended.
• Thiazide diuretics + Vitamin D3: May increase risk of hypercalcemia. Calcium monitoring is appropriate.
• Granulomatous diseases (sarcoidosis, TB): These conditions increase endogenous D3 activation — supplementation may cause hypercalcemia. Consult a physician before use.
• Fish allergy: Wiley’s Finest contains Alaska Pollock — contraindicated in fish allergy.

Dosing Guidance

• Vitamin D3: 1,000–2,000 IU/day for general maintenance in adults. Repletion of documented deficiency typically requires higher doses under pharmacist or physician guidance. Blood level testing (25(OH)D) guides dosing.
• Vitamin K2 (MK-7): 90–200 mcg/day. The Knapen 2013 RCT used 180 mcg/day; the low-dose K2 RCT (PMID 32060566) used 90 mcg/day in postmenopausal women.
• Omega-3: 500–1,000 mg EPA+DHA/day for general health support.

Who May Consider D3 + K2?

• Adults with documented or likely vitamin D deficiency
• Postmenopausal women with bone health concerns — where both D3 and K2 have the strongest supporting evidence
• Patients already taking D3 who wish to discuss K2 addition with a pharmacist
• Adults with limited sun exposure in northern latitudes
• Patients with established cardiovascular disease or concerns about vascular calcification who wish to discuss the emerging K2 evidence with their physician or pharmacist

Pharmacist’s Perspective

As a PharmD, I discuss vitamin D3 with patients routinely — it is one of the most clinically relevant nutrients to assess, particularly in populations with limited sun exposure, older adults, and patients with bone health concerns. The evidence for correcting vitamin D deficiency is well-established. The rationale for adding K2 alongside D3 is biologically sound and supported by promising RCT data, particularly for postmenopausal women and — based on a 2026 randomized trial — patients with established coronary artery disease interested in slowing calcification progression. I discuss K2 as a reasonable consideration for appropriate patients — not a universal requirement — and always with a review of the patient’s anticoagulant medications first.

Free PharmD consultation available by phone or in-store: (408) 622-8068.

Frequently Asked Questions

Q: How do I know if I’m vitamin D deficient?
A: A blood test measuring 25(OH)D levels is the standard assessment. We recommend testing if you live in northern California, work indoors, or have risk factors. Ask our PharmD for guidance.

Q: Can I take too much Vitamin D3?
A: Vitamin D toxicity can occur at very high, sustained doses. At 1,000–2,000 IU/day, toxicity is extremely unlikely. Blood level monitoring is appropriate for doses above 4,000 IU/day.

Q: I’m on warfarin. Can I take K2?
A: Only with physician supervision and INR monitoring. Do not start any vitamin K supplement while on warfarin without consulting your pharmacist and physician first.

Q: Should I take D3 with food?
A: Yes — D3 is fat-soluble and is better absorbed with a meal containing fat. Combination softgels like Wiley’s Finest already include fish oil, which supports absorption.

Related Clinical Insights Articles

• What Is Fucoidan? A Pharmacist’s Guide →
• AHCC: A Pharmacist’s Evidence Review →

Reviewed by:

Dai Tran, PharmD, MBA, B.S. • View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com